ABUS vs FFIV · P/E 5.4, rev $6.2M vs P/E 32, rev $3.09B
Arbutus Biopharma Corp (ABUS) versus F5 Networks Inc (FFIV) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
F5 Networks Inc (FFIV) is a software - infrastructure company listed on NASDAQ.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported FFIV revenue for 2025-09-30 was $3.09B. Net income was $692.4M. Revenue was up 9.7% from 2024-09-30 to 2025-09-30. FFIV currently screens at market cap $21.71B and trailing P/E 31.6.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. FFIV currently screens at market cap $21.71B and trailing P/E 31.6.
Not investment advice. Open the ABUS and FFIV stock pages for the full models.
Not investment advice.